#1
|
|||
|
|||
A patients’ decisional conflict score ( improved by 6% ).
×àñòîòà "ñîìíåíèÿ â ïðàâèëüíîñòè ëå÷åíèÿ"? |
#2
|
||||
|
||||
Îöåíêà "ñîìíåíèé ïàöèåíòà â ïðàâèëüíîñòè âûáîðà ëå÷åíèÿ" (â âèäå øêàëû)
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
|||
|
|||
Ìîæåò áîëüøå ê àíãèîõèðóðãàì:
In-stent late loss at 9 months in workhorse lesion subset Workhorse lesions: (visual RVD >2.5 & <4.25mm; visual lesion length <24mm). Åñòü óñòîé÷èâîå ðóññêîÿçû÷íîå âûðàæåíèå äëÿ ðàáî÷åé ëîøàäêè? |
#4
|
||||
|
||||
Öèòàòà:
 äàííîì ñëó÷àå, ÿ äóìàþ, èìååò ñìûñë ïåðåâåñòè êàê "íàèáîëåå ÷àñòûå". |
#5
|
|||
|
|||
Öèòàòà:
Èëè ýòî òå, äëÿ êîòîðûõ õàðàêòåðíà ìèãðàöèÿ ñòåíòà? Ñóäÿ ïî ýòîìó òåêñòó: The PROMUS Element TM stent is the everolimus-coated member of the platinum chromium (PtCr) ElementTM Stent Series. The Element stent delivery system is available in four stent models, each engineered for specific diameters to provide consistent stent-to-artery ratios across the range of reference vessel diameters indicated: - Small Vessel (SV): 2.25 mm - Small Workhorse (SWH): 2.50, 2.75 mm - Workhorse (WH): 3.00, 3.50 mm - Large Vessel (LV): 4.00 mm |
#6
|
||||
|
||||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#7
|
|||
|
|||
visual RVD >2.5 & <4.25mm; visual lesion length <24mm - ýòî îêîëî 80% âñåõ ñòåíîçîâ, åñëè àíãëèéñêàÿ ôðàçåîëîãèÿ äîïóñêàåò ñëîâî Workhorse ïðèìåíèòåëüíî ê òîìó, ÍÀÄ ÷åì ìû ðàáîòàåì, à íå òîëüêî ê òîìó, ×ÅÌ ìû ðàáîòàåì, òî ÿ áû ôîðìóëèðîâàë ïðåäëîæåíèå ñ ôðàçîé "îñíîâíîé õëåá"
Àïïåíäèöèò - "îñíîâíîé õëåá" äåæóðíîãî õèðóðãà. Ïåðåëîì ëó÷à â òèïè÷íîì ìåñòå - "îñíîâíîé õëåá" âðà÷à òðàâìîïóíêòà. Ñòåíîçû ñîñóäîâ >2.5 & <4.25mm; äëèíîé <24mm - îñíîâíîé õëåá èíòåðâåíöèîííîãî êàðäèîëîãà. Åñëè "æàíð ïðîèçâåäåíèÿ" òàêîé ïåðåâîä ïîçâîëÿåò |
|
#8
|
|||
|
|||
|
#9
|
|||
|
|||
The first study, TAXUS PERSEUS Workhorse (A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions), will evaluate the safety and efficacy of the TAXUS Element Stent compared to Boston Scientific's first generation drug-eluting stent, the TAXUS® Express2™ Stent. This study will evaluate 1,264 patients with "workhorse" lesions from 2.75 to 4.0 millimeters. The primary endpoint of the workhorse study is target lesion failure (TLF) at 12 months, and its secondary endpoint is in-segment percent diameter stenosis at nine months.
Ñóäÿ ïî òàêîé ïîñòàíîâêå âîïðîñà ìíå êàæåòñÿ àäåêâàòíûì "íàèáîëåå ÷àñòûå" |
#10
|
||||
|
||||
Òåïåðü åùå áîëüøå ïîõîæå íà íàèìåíîâàíèå êàëèáðà ñîñóäîâ. Ìåëêèå, êðóïíûå, à ìåæäó íèìè ïðîìåæóòî÷íûå - ðàáî÷àÿ ëîøàäêà è ëîøàäêà.
Èíòåðåñíî áû äîæäàòüñÿ ìíåíèÿ àíãèîõèðóðãîâ. ×òî êàñàåòñÿ íàèáîëåå ÷àñòûõ, ïî âñåé âèäèìîñòè - íàèáîëåå ÷àñòî ïîðàæàåìûå. |
#11
|
|||
|
|||
Öèòàòà:
* Öèòàòà:
|
#12
|
|||
|
|||
Óâàæàåìûå êîëëåãè! Áîëüøîå ñïàñèáî çà îêàçàííóþ ïîìîùü.
Îòäåëüíûå ñëîâà ïåðåâîæó, ñìûñë íå ïîíèìàþ. Ðå÷ü èäåò î ïîêàçàíèÿõ ê ïðèìåíåíèþ íîñîâûõ êàíþëü äëÿ êèñëîðîäà: Patients with adequate spontaneous respiratory effort, airway protective mechanism, and tidal volume è åùå- ventilatory drive...
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#13
|
|||
|
|||
À ïîëíóþ öèòàòó (ôðàãìåíò/àáçàö) - ìîæíî?
|
#14
|
|||
|
|||
The nasal cannula (Figure 1) is a low-flow oxygen administration system designed to add oxygen to room air when the patient inspires.
Indications: Patients with adequate spontaneous respiratory effort, airway protective mechanism, and tidal volume Patients with arterial oxyhemoglobin saturation <94% Patients with minimal respiratory or oxygenation problems Patients who cannot tolerate a face mask Never withhold oxygen from patients who have respiratory distress and severe hypoxemia simply because you suspect a hypoxic ventilatory drive. If oxygen administration depresses respiration, support ventilation. |
#15
|
|||
|
|||
Âîçìîæíî ï.1
- Ïàöèåíòàì ñ àäåêâàòíûì ñàìîñòîÿòåëüíûì äûõàíèåì â êà÷åñòâå ñïîñîáà çàùèòû äûõàòåëüíûõ ïóòåé è îáåñïå÷åíèÿ àäåêâàòíîãî ïîòîêà âîçäóõà; ... hypoxic ventilatory drive - ? ÿ ïàñ... |